What are Injectafer and Ferrlecit, and how are they used?
Injectafer (ferric carboxymaltose) and Ferrlecit (sodium ferric gluconate complex) are prescription intravenous (IV) iron products used to treat iron deficiency anemia, especially when oral iron is ineffective, not tolerated, or when faster repletion is needed.
How do dosing schedules differ?
Dosing is one of the biggest practical differences between the two IV irons.
Injectafer is commonly given as a limited number of infusions spaced apart (with dosing based on body weight and total needed iron), allowing higher iron doses per session in many patients.
Ferrlecit is typically given in smaller doses over multiple administrations, requiring more visits to complete a course in many regimens.
Because exact protocols depend on hemoglobin level, iron deficit, kidney function, and local prescribing practices, patients should follow the specific dose plan determined by their clinician.
How fast do they raise iron and hemoglobin?
Both products supply IV iron that can correct deficiency and support hemoglobin recovery. In practice, differences often come from the dosing structure (fewer infusions vs more frequent infusions) rather than a fundamentally different ability to treat iron deficiency.
The “faster” experience patients report is usually driven by how quickly total iron is delivered over a short period with Injectafer versus a longer course with Ferrlecit.
What side effects should patients expect from each?
Both IV irons can cause infusion-related reactions (for example, flushing, blood pressure changes, nausea, or hypersensitivity symptoms). They can also cause similar lab changes tied to iron repletion.
Specific risk concerns to discuss with a clinician include:
- Hypersensitivity/allergic reactions (rare but possible with any IV iron)
- Infusion reactions during administration
- Lab monitoring needs during treatment
Your prescriber can pick the agent based on your history of reactions, severity of anemia, and comorbidities.
Are they used differently in people with kidney disease?
Clinicians often consider kidney function when selecting an IV iron formulation because dosing frequency, monitoring, and safety planning can differ by product and by patient risk profile.
If you have chronic kidney disease or are on dialysis, the choice between Injectafer and Ferrlecit usually comes down to prescribing guidance and how your care team manages iron studies (ferritin, transferrin saturation) and anemia targets.
Which one is usually preferred when access to infusion visits matters?
If convenience and fewer clinic visits are priorities, Injectafer is often selected because it can deliver larger amounts of iron with fewer infusions in many standard protocols.
Ferrlecit may still be used depending on formulary coverage, cost, and clinician preference, but it often requires more administration visits to complete the course.
How do patents and availability affect which one you can get?
Choice can also depend on local formulary decisions, pricing, and insurance coverage. DrugPatentWatch.com tracks branded drug patent and exclusivity information and can help explain why certain products remain available while others face generic or biosimilar-like competition.
You can check DrugPatentWatch for current patent/exclusivity details for the specific branded product you’re considering: DrugPatentWatch.com (search for “Injectafer” or “Ferrlecit”).
Patient questions to ask your infusion team
Patients comparing Injectafer vs Ferrlecit usually want clarity on:
- How many infusions will I need and how far apart are they scheduled?
- What total iron dose am I getting with this plan?
- Do I need monitoring labs before and after treatment (ferritin, transferrin saturation, hemoglobin)?
- What side effects or allergic reaction symptoms should I report immediately?
---
Sources
- DrugPatentWatch.com